<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font14 { font-size : 14; } .font15 { font-size : 15; } .font16 { font-size : 16; } .font17 { font-size : 17; } .font18 { font-size : 18; } .font20 { font-size : 20; } .font22 { font-size : 22; } .font26 { font-size : 26; } .font27 { font-size : 27; } .font28 { font-size : 28; } .font30 { font-size : 30; } .font31 { font-size : 31; }</style>
 <body>
  <p>
   <span class="font31">treatment </span>
   <span class="font30">virus </span>
   <span class="font28">activity </span>
   <span class="font27">antiviral </span>
   <span class="font26">drugs </span>
   <span class="font26">DNA </span>
   <span class="font26">viral </span>
   <span class="font22">drug </span>
   <span class="font22">approved </span>
   <span class="font20">analogue </span>
   <span class="font20">nucleoside </span>
   <span class="font20">combination </span>
   <span class="font18">clinical </span>
   <span class="font18">tenofovir </span>
   <span class="font18">used </span>
   <span class="font18">active </span>
   <span class="font18">cancer </span>
   <span class="font18">gemcitabine </span>
   <span class="font17">HBV </span>
   <span class="font17">HIV </span>
   <span class="font17">HIV- </span>
   <span class="font17">analogues </span>
   <span class="font17">hepatitis </span>
   <span class="font16">infections </span>
   <span class="font16">{border-style </span>
   <span class="font16">herpes </span>
   <span class="font16">px;} </span>
   <span class="font15">#ffffff;} </span>
   <span class="font15">VZV </span>
   <span class="font15">acyclovir </span>
   <span class="font15">viruses </span>
   <span class="font15">disoproxil </span>
   <span class="font15">inhibits </span>
   <span class="font15">shown </span>
   <span class="font15">broad-spectrum </span>
   <span class="font15">human </span>
   <span class="font14">cell </span>
   <span class="font14">cellular </span>
   <span class="font14">inhibitor </span>
   <span class="font14">inhibitors </span>
   <span class="font14">use </span>
   <span class="font14">Fig. </span>
   <span class="font14">HCV </span>
   <span class="font14">development </span>
   <span class="font14">group </span>
   <span class="font14">nucleos(t)ide-based </span>
   <span class="font14">trials </span>
   <span class="font13">Agents </span>
   <span class="font13">HSV- </span>
   <span class="font13">RNA </span>
   <span class="font13">antineoplastic </span>
   <span class="font13">infection </span>
   <span class="font13">study </span>
   <span class="font13">Res../j.antiviral... </span>
   <span class="font13">cells </span>
   <span class="font13">chronic </span>
   <span class="font13">effective </span>
   <span class="font13">oral </span>
   <span class="font13">patients </span>
   <span class="font13">therapy </span>
   <span class="font13">thymidine </span>
   <span class="font13">triphosphate </span>
   <span class="font13">(De </span>
   <span class="font13">Gilead </span>
   <span class="font13">agents </span>
   <span class="font13">caused </span>
   <span class="font13">decitabine </span>
   <span class="font13">lamivudine </span>
   <span class="font13">phase </span>
   <span class="font13">reverse </span>
   <span class="font13">safety </span>
   <span class="font13">type </span>
   <span class="font13">vitro </span>
   <span class="font12">(Clouser </span>
   <span class="font12">(e.g., </span>
   <span class="font12">(phase </span>
   <span class="font12">Acyclic </span>
   <span class="font12">FDA </span>
   <span class="font12">HSV </span>
   <span class="font12">HSV, </span>
   <span class="font12">Sciences, </span>
   <span class="font12">Table </span>
   <span class="font12">acyclic </span>
   <span class="font12">acyclovir, </span>
   <span class="font12">antivirals </span>
   <span class="font12">azacytidine </span>
   <span class="font12">chain </span>
   <span class="font12">currently </span>
   <span class="font12">effect </span>
   <span class="font12">efficacy </span>
   <span class="font12">form </span>
   <span class="font12">guanosine </span>
   <span class="font12">herpesviruses </span>
   <span class="font12">mechanism </span>
   <span class="font12">nucleotide </span>
   <span class="font12">px; </span>
   <span class="font12">review </span>
   <span class="font12">ribonucleotide </span>
   <span class="font12">zoster </span>
   <span class="font12">{font-family </span>
   <span class="font12">(Beach </span>
   <span class="font12">(Ianevski </span>
   <span class="font12">(NCT). </span>
   <span class="font12">Additionally, </span>
   <span class="font12">Approved </span>
   <span class="font12">Med. </span>
   <span class="font12">Sofosbuvir </span>
   <span class="font12">acid </span>
   <span class="font12">available </span>
   <span class="font12">based </span>
   <span class="font12">compound </span>
   <span class="font12">effects </span>
   <span class="font12">font-size </span>
   <span class="font12">growth </span>
   <span class="font12">herpesvirus </span>
   <span class="font12">high </span>
   <span class="font12">infections. </span>
   <span class="font12">inhibition </span>
   <span class="font12">multi-target </span>
   <span class="font12">novel </span>
   <span class="font12">nucleos(t)ide </span>
   <span class="font12">observed </span>
   <span class="font12">phosphorylated </span>
   <span class="font12">polymerase </span>
   <span class="font12">prodrug </span>
   <span class="font12">reported </span>
   <span class="font12">results </span>
   <span class="font12">revealed </span>
   <span class="font12">similar </span>
   <span class="font12">simplex </span>
   <span class="font12">substrate </span>
   <span class="font12">toxicity </span>
   <span class="font12">valaciclovir </span>
   <span class="font12">(Jordheim </span>
   <span class="font12">(Rawson </span>
   <span class="font12">CMV </span>
   <span class="font12">Chemother../aac.- </span>
   <span class="font12">Clercq, </span>
   <span class="font12">EBV </span>
   <span class="font12">However, </span>
   <span class="font12">Unfortunately, </span>
   <span class="font12">Vidarabine </span>
   <span class="font12">Zika </span>
   <span class="font12">action </span>
   <span class="font12">antibacterial </span>
   <span class="font12">bioavailability </span>
   <span class="font12">breast </span>
   <span class="font12">compounds </span>
   <span class="font12">concentrations </span>
   <span class="font12">converted </span>
   <span class="font12">cytotoxic </span>
   <span class="font12">double; </span>
   <span class="font12">fever </span>
   <span class="font12">ganciclovir </span>
   <span class="font12">herpesviruses. </span>
   <span class="font12">higher </span>
   <span class="font12">highly </span>
   <span class="font12">inhibit </span>
   <span class="font12">kinase </span>
   <span class="font12">polymerase. </span>
   <span class="font12">pyrimidine </span>
   <span class="font12">recently </span>
   <span class="font12">replication </span>
   <span class="font12">ribavirin </span>
   <span class="font12">showed </span>
   <span class="font12">significant </span>
   <span class="font12">sofosbuvir </span>
   <span class="font12">studies </span>
   <span class="font12">synergistic </span>
   <span class="font12">synthesis </span>
   <span class="font12">trial </span>
   <span class="font11">(Kang </span>
   <span class="font11">(emtricitabine </span>
   <span class="font11">)HIV- </span>
   <span class="font11">-azacytidine </span>
   <span class="font11">Acyclovir </span>
   <span class="font11">Chem. </span>
   <span class="font11">Elsevier </span>
   <span class="font11">FLUAV </span>
   <span class="font11">Gemcitabine </span>
   <span class="font11">Lamivudine </span>
   <span class="font11">Nucleoside </span>
   <span class="font11">Tenofovir </span>
   <span class="font11">VZV, </span>
   <span class="font11">ViiV </span>
   <span class="font11">Zhou, </span>
   <span class="font11">acute </span>
   <span class="font11">adenosine </span>
   <span class="font11">advanced </span>
   <span class="font11">agent </span>
   <span class="font11">alafenamide </span>
   <span class="font11">animal </span>
   <span class="font11">anticancer </span>
   <span class="font11">antimetabolites </span>
   <span class="font11">border-color </span>
   <span class="font11">border-width </span>
   <span class="font11">cases </span>
   <span class="font11">cause </span>
   <span class="font11">cells. </span>
   <span class="font11">comparison </span>
   <span class="font11">developed </span>
   <span class="font11">different </span>
   <span class="font11">drug, </span>
   <span class="font11">enzymes </span>
   <span class="font11">famciclovir </span>
   <span class="font11">idoxuridine </span>
   <span class="font11">immune </span>
   <span class="font11">including </span>
   <span class="font11">infected </span>
   <span class="font11">leukaemia </span>
   <span class="font11">low </span>
   <span class="font11">metastatic </span>
   <span class="font11">million </span>
   <span class="font11">multiple </span>
   <span class="font11">mutagenesis </span>
   <span class="font11">number </span>
   <span class="font11">pancreatic </span>
   <span class="font11">penciclovir </span>
   <span class="font11">potent </span>
   <span class="font11">range </span>
   <span class="font11">reductase </span>
   <span class="font11">research </span>
   <span class="font11">selective </span>
   <span class="font11">significantly </span>
   <span class="font11">solid; </span>
   <span class="font11">strains </span>
   <span class="font11">syndrome </span>
   <span class="font11">synergy </span>
   <span class="font11">transcriptase </span>
   <span class="font11">treat </span>
   <span class="font11">types </span>
   <span class="font11">{font-style </span>
   <span class="font11">{font-weight </span>
   <span class="font11">(Alexeeva </span>
   <span class="font11">(Littler </span>
   <span class="font11">(NCT) </span>
   <span class="font11">(lamivudine </span>
   <span class="font11">According </span>
   <span class="font11">AdV </span>
   <span class="font11">COVID- </span>
   <span class="font11">Clofarabine </span>
   <span class="font11">Currently, </span>
   <span class="font11">Gemzar </span>
   <span class="font11">HHV- </span>
   <span class="font11">HIV, </span>
   <span class="font11">HSV-, </span>
   <span class="font11">Health </span>
   <span class="font11">Healthcare, </span>
   <span class="font11">Lamont, </span>
   <span class="font11">Moreover, </span>
   <span class="font11">Mylan </span>
   <span class="font11">Opin. </span>
   <span class="font11">Pharmaceuticals, </span>
   <span class="font11">Recently, </span>
   <span class="font11">Res. </span>
   <span class="font11">Trifluridine </span>
   <span class="font11">United </span>
   <span class="font11">Virol../jvi.- </span>
   <span class="font11">ZIKV </span>
   <span class="font11">absorbed </span>
   <span class="font11">act </span>
   <span class="font11">activities </span>
   <span class="font11">administration </span>
   <span class="font11">agent. </span>
   <span class="font11">amino </span>
   <span class="font11">and/or </span>
   <span class="font11">anti-HIV </span>
   <span class="font11">antimetabolite </span>
   <span class="font11">applied </span>
   <span class="font11">better </span>
   <span class="font11">bladder </span>
   <span class="font11">bold </span>
   <span class="font11">brivudine </span>
   <span class="font11">cancer. </span>
   <span class="font11">candidates </span>
   <span class="font11">causes </span>
   <span class="font11">centre </span>
   <span class="font11">colorectal </span>
   <span class="font11">commonly </span>
   <span class="font11">courier; </span>
   <span class="font11">cytidine </span>
   <span class="font11">data </span>
   <span class="font11">demonstrated </span>
   <span class="font11">described </span>
   <span class="font11">diseases </span>
   <span class="font11">drug-resistant </span>
   <span class="font11">em; </span>
   <span class="font11">emtricitabine </span>
   <span class="font11">enzyme </span>
   <span class="font11">ester </span>
   <span class="font11">exhibit </span>
   <span class="font11">immunodeficiency </span>
   <span class="font11">important </span>
   <span class="font11">include </span>
   <span class="font11">incorporated </span>
   <span class="font11">increase </span>
   <span class="font11">increased </span>
   <span class="font11">metabolite </span>
   <span class="font11">natural </span>
   <span class="font11">new </span>
   <span class="font11">non-nucleoside </span>
   <span class="font11">polymerases </span>
   <span class="font11">preclinical </span>
   <span class="font11">prodrugs </span>
   <span class="font11">pt;} </span>
   <span class="font11">rate </span>
   <span class="font11">reduced </span>
   <span class="font11">reduction </span>
   <span class="font11">related </span>
   <span class="font11">replaced </span>
   <span class="font11">resource </span>
   <span class="font11">ring </span>
   <span class="font11">strategies </span>
   <span class="font11">tested </span>
   <span class="font11">transcription </span>
   <span class="font11">transporters </span>
   <span class="font11">treatments </span>
   <span class="font11">using </span>
   <span class="font11">valaciclovir, </span>
   <span class="font11">vidarabine </span>
   <span class="font11">wide </span>
  </p>
 </body>
</html>
